Updated: January 24, 2026

EstroGel Shortage: What Providers and Prescribers Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Current Status: Not an Official Shortage, But a Real Access Problem
Timeline of Contributing Factors
Clinical Implications for Your Patients
Therapeutically Equivalent Alternatives to EstroGel
Prescribing Strategies to Improve Fill Rates
Patient Education Points

A clinical briefing on EstroGel availability challenges in 2026, including prescribing alternatives, dose equivalencies, and tools to help patients find their medication.

If your patients have been reporting difficulty filling their EstroGel (estradiol 0.06% gel) prescriptions, you are not alone. While EstroGel is not currently listed on the FDA's official drug shortage database, a perfect storm of demand-side pressures has made it genuinely difficult for many patients to access at their local pharmacies in 2026. This briefing provides a clinical summary of the situation and practical guidance for prescribers.

Current Status: Not an Official Shortage, But a Real Access Problem

EstroGel is not on the FDA's drug shortage list as of 2026, and ASCEND Therapeutics has not announced manufacturing disruptions. However, the combination of the November 2025 FDA black box warning removal from HRT products and the ongoing nationwide estradiol patch shortage has created significant demand pressure on estradiol gels. Many pharmacies — particularly chain pharmacies in suburban and rural areas — lack the inventory to meet this elevated demand, resulting in localized stockouts that patients experience as a shortage.

Timeline of Contributing Factors

2020–2024: Telehealth menopause platforms (Midi Health, Alloy, Evernow) steadily increased HRT prescription volume, elevating baseline demand for transdermal estradiol products.

Late 2024 – 2025: Estradiol transdermal patches began experiencing persistent supply disruptions. Climara was discontinued by Bayer in late 2023, reducing the number of patch manufacturers. Remaining manufacturers (Amneal, Sandoz, Mylan, Zydus, Noven) have faced production constraints.

November 2025: FDA removed the black box warning from bioidentical transdermal estradiol products. This evidence-based change triggered an immediate surge in new HRT prescriptions from both new patients and newly comfortable providers.

Late 2025 – 2026: Patch shortages intensified. Providers began prescribing gels (EstroGel, Divigel) as transdermal alternatives, dramatically increasing gel demand without a corresponding supply ramp.

Clinical Implications for Your Patients

Patients may present with unfilled or partially filled EstroGel prescriptions. Some may be rationing their remaining supply, which can result in subtherapeutic dosing and return of vasomotor symptoms. Others may have obtained inadequate advice to simply stop their HRT without medical guidance, which can lead to an abrupt return of menopause symptoms.

Therapeutically Equivalent Alternatives to EstroGel

The following FDA-approved alternatives can be considered when EstroGel is unavailable. Note that dose equivalence across formulations is approximate, and clinical follow-up after switching is advisable:

Divigel (estradiol gel 0.1%) or generic estradiol gel 0.1%: EstroGel 1.25 g/day (0.75 mg) ≈ Divigel 0.5 g/day (0.5 mg) or Divigel 0.75 g/day (0.75 mg). Generic estradiol gel 0.1% is available at $32–$50/month with discount coupons. Applied to the upper thigh.

Elestrin (estradiol gel 0.06%): Same concentration as EstroGel; applied to upper arm; may allow direct substitution by pump count. Brand-name only.

Evamist (estradiol topical spray): 1 spray/day = ~90 mcg/day systemic estradiol. Transdermal; bypasses first-pass metabolism. May be suitable where gel adherence is a challenge.

Oral estradiol (generic tablets): Widely available, $4–$15/month. Bioequivalent doses: oral estradiol 1 mg/day ≈ EstroGel 1.25 g/day. Note: first-pass hepatic metabolism increases VTE risk modestly compared to transdermal. Not recommended for patients with active VTE risk factors, migraines with aura, or hepatic disease.

Prescribing Strategies to Improve Fill Rates

Use therapeutic substitution language: "EstroGel 0.06% 1.25 g/day, or therapeutically equivalent estradiol gel" — this gives pharmacists flexibility to dispense Divigel or generic gel without a new script.

Call ahead to confirm stock before sending e-prescriptions to a specific pharmacy — particularly for patients with known difficulty filling.

Prescribe 90-day supplies when available to reduce the frequency of fill issues.

Direct patients to mail-order pharmacies for better inventory and delivery convenience.

Patient Education Points

Counsel patients on the following:

Do not stop HRT abruptly. Abrupt cessation causes rapid return of vasomotor symptoms, sleep disruption, and mood changes.

Refill early — at least 7 days before running out — particularly given current filling delays.

Independent pharmacies and mail-order pharmacies may have better EstroGel inventory than large chain pharmacies.

medfinder for Providers at medfinder.com/providers allows your patients to search for nearby pharmacies with EstroGel in stock, reducing the burden on your staff to make pharmacy calls.

Also see: How to Help Your Patients Find EstroGel in Stock and EstroGel Shortage Update: What Patients Need to Know.

Frequently Asked Questions

No. EstroGel is not on the FDA's official drug shortage list as of 2026. ASCEND Therapeutics has not announced manufacturing disruptions. The access problems patients are experiencing are driven by a demand surge — from the FDA's November 2025 black box warning removal and overflow from the estradiol patch shortage — rather than a production failure.

The closest alternative is generic estradiol gel 0.1% (Divigel brand), applied to the upper thigh. Approximate dose equivalence: EstroGel 1.25 g/day ≈ generic estradiol gel 0.1% at 0.75 g/day. Generic estradiol gel 0.1% is widely available and significantly less expensive than EstroGel. Elestrin (estradiol 0.06% gel) offers the same concentration as EstroGel and may allow simpler substitution.

Oral estradiol is appropriate for many patients and is widely available at low cost. However, due to hepatic first-pass metabolism, oral estradiol carries a modestly higher VTE risk compared to transdermal options. For patients with VTE risk factors, migraines with aura, hepatic disease, or cardiovascular concerns, maintaining transdermal delivery (gel or spray) is clinically preferable. Discuss individual risk profiles before switching routes.

Use therapeutic substitution language on the prescription: 'Estradiol 0.75 mg/day transdermal gel (EstroGel 0.06% preferred, or therapeutically equivalent).' This allows the pharmacist to dispense generic estradiol gel 0.1% or Elestrin without requiring a new prescription, improving the likelihood that patients can fill their prescription at the first pharmacy they contact.

medfinder.com is a service that calls pharmacies near the patient to check which ones can fill their EstroGel prescription. Patients can also check mail-order pharmacies and independent pharmacies, which often have better access to specialty medications during periods of elevated chain pharmacy demand. GoodRx can help identify participating pharmacies and reduce out-of-pocket cost, but does not show real-time inventory.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards